Posts

Sensorion advances hearing loss gene therapy programs

on

Servier inks up to $2.65B buyout of Edgewise's muscular dystrophy unit to boost neurology pipeline

on

After Tumultuous Year, Sarepta Plots Rebound with Early Data on RNA Therapies

on

Entrada tightens focus on Duchenne, axes 20% of staff

on

Biotech Restructuring and European Regulatory Setbacks

on

Wave Life Sciences' WVE-N531 Shows Promise in Duchenne Muscular Dystrophy Treatment

on

Epicrispr raises $68M, will start clinical trial of epigenetic editing for FSHD

on

Sarepta Reports Death of DMD Patient Following Elevidys Gene Therapy Treatment

on

Avidity's Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment

on

Entrada given go-ahead to test DMD therapy after two-year hold

on

FDA Lifts Clinical Hold on Entrada's Duchenne Muscular Dystrophy Drug ENTR-601-44 After Two Years

on

Solid Biosciences' DMD Gene Therapy Shows Promising Early Results, Driving Stock Surge

on

Sarepta Therapeutics Reports Encouraging Two-Year Data for ELEVIDYS in Duchenne Muscular Dystrophy, Projecting $1 Billion in Sales

on